JP2014518198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518198A5 JP2014518198A5 JP2014513193A JP2014513193A JP2014518198A5 JP 2014518198 A5 JP2014518198 A5 JP 2014518198A5 JP 2014513193 A JP2014513193 A JP 2014513193A JP 2014513193 A JP2014513193 A JP 2014513193A JP 2014518198 A5 JP2014518198 A5 JP 2014518198A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- glu
- set forth
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001413 amino acids Chemical class 0.000 claims 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- 102220638483 Protein PML_K65R_mutation Human genes 0.000 claims 1
- 102220482677 Uncharacterized protein EXOC3-AS1_A61S_mutation Human genes 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102220259319 rs1553651734 Human genes 0.000 claims 1
- 102220122856 rs201556985 Human genes 0.000 claims 1
- 102220036189 rs273585616 Human genes 0.000 claims 1
- 102220040126 rs371657037 Human genes 0.000 claims 1
- 102200080116 rs556297791 Human genes 0.000 claims 1
- 102220041067 rs587778601 Human genes 0.000 claims 1
- 102220088977 rs869312698 Human genes 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168327 | 2011-05-31 | ||
| EP11168327.2 | 2011-05-31 | ||
| US201161492990P | 2011-06-03 | 2011-06-03 | |
| US61/492,990 | 2011-06-03 | ||
| PCT/EP2012/060248 WO2012164021A1 (en) | 2011-05-31 | 2012-05-31 | Il-21 epitope and il-21 ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014518198A JP2014518198A (ja) | 2014-07-28 |
| JP2014518198A5 true JP2014518198A5 (cg-RX-API-DMAC7.html) | 2015-07-16 |
Family
ID=47258396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513193A Withdrawn JP2014518198A (ja) | 2011-05-31 | 2012-05-31 | Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140170153A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2714198A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014518198A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103702721A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012164021A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014205501A1 (en) * | 2013-06-27 | 2014-12-31 | Monash University | Il-21 binding proteins and uses thereof |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| PT3139948T (pt) * | 2014-05-07 | 2020-05-22 | Novo Nordisk As | Tratamento de diabetes usando glp-1 e anti-il-21 |
| JP6672175B2 (ja) * | 2014-05-07 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療 |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| CN107249633A (zh) * | 2014-12-19 | 2017-10-13 | 迈博太科公司 | 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法 |
| MX2020005208A (es) * | 2017-12-06 | 2020-08-20 | Pandion Operations Inc | Muteinas de interleucina 2 (il-2) y usos de estas. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| PL1963369T3 (pl) * | 2005-11-28 | 2013-10-31 | Zymogenetics Inc | Antagoniści IL-21 |
| WO2009047360A1 (en) * | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
| EP2426146B1 (en) * | 2007-12-07 | 2016-02-17 | ZymoGenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
-
2012
- 2012-05-31 JP JP2014513193A patent/JP2014518198A/ja not_active Withdrawn
- 2012-05-31 US US14/122,572 patent/US20140170153A1/en not_active Abandoned
- 2012-05-31 WO PCT/EP2012/060248 patent/WO2012164021A1/en not_active Ceased
- 2012-05-31 EP EP12727128.6A patent/EP2714198A1/en not_active Withdrawn
- 2012-05-31 CN CN201280037924.8A patent/CN103702721A/zh not_active Withdrawn